Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

Clarivate Plc has announced a definitive agreement to divest its Life Sciences & Healthcare (LS&H) segment to Altaris LLC for $600 million. This transaction, which is expected to close by the end of 2023, is part of Clarivate's strategy to sharpen its focus on its Academia & Government and Intellectual Property segments. The deal is anticipated to enhance Clarivate's financial profile by improving its revenue mix, expanding its Adjusted EBITDA margin, and lowering capital intensity.

Clarivate, a leading global provider of transformative intelligence, aims to streamline its operations by concentrating on its subscription-first offerings in the A&G and IP sectors. These segments already benefit from established customer relationships and shared content assets, positioning Clarivate to drive sustained value through differentiated insights and tech-enabled services. The divestiture aligns with the company's four-pillared Value Creation Plan, which seeks to optimize its business model and accelerate innovation while rationalizing its portfolio.

The proceeds from the sale will be directed towards debt reduction, strengthening Clarivate's balance sheet and providing greater financial flexibility for future growth initiatives. The transaction is structured to provide Clarivate with $500 million in cash at closing, along with a deferred payment of $25 million and a $75 million seller note. This strategic move is expected to enhance the quality of Clarivate's revenue mix and improve margins, as the company transitions to a more focused operational structure.

Altaris LLC, known for its exclusive focus on acquiring and building companies within the healthcare industry, is well-positioned to support the LS&H segment's growth. The division integrates deep domain expertise and strong analytical capabilities to aid customers throughout the drug and device lifecycle. Under Altaris' ownership, the segment is expected to leverage continued investment and a strong emphasis on customer impact to build on its existing foundation.

The broader implications of this transaction reflect ongoing trends in the healthcare and technology sectors, where companies are increasingly seeking to optimize their portfolios and focus on core competencies. As Clarivate pivots towards AI-driven solutions in academia and intellectual property, the divestiture may signal a shift in strategic priorities for similar firms in the industry. This transaction highlights the importance of aligning business operations with market demands and shareholder value creation, setting a precedent for future M&A activity in the sector.